Psoriasis, An Overview of its Pathogenesis and Available Treatment Modalities
-
Published:2022-10-30
Issue:2
Volume:2022
Page:1-5
-
ISSN:2816-8119
-
Container-title:Albus Scientia
-
language:
-
Short-container-title:Albus Scientia
Author:
Salahuddin Zari, Usman Ali Khan Muhammad, Akhtar TasleemORCID
Abstract
Psoriasis is a chronic inflammatory and genetic disease that mainly involves skin with some complicated forms extending to other body systems. The disease is fairly common with genetic predisposition as one of the major etiology. It is known to occur as a result of immune system aberration involving helper T cells mainly and is thus treated on similar lines with most of the drugs belonging to immunomodulator class like steroids, calcineurin inhibitors, methotrexate and various others like retinoids. Disease pathology has a new area of research advancement focused on oxidative stress. It has been suggested that reactive oxygen species have a considerable role in the cascade of pathological features. The disease shows relapses and remissions seldom showing a remarkable or complete recovery. A therapy which can completely resolve the cosmetic and other important symptoms is still a food for research. The dimensions of research have also been inclined to nano particles as treatment options over past few years. In this review, our key objective is to highlight the complexity and clinical diversity of this multifaceted disorder, its pathogenesis and the potential of state of the art treatment options.
Publisher
Albus Scientific Inc.
Reference32 articles.
1. Alexis, A. F., & Blackcloud, P. (2014). Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. The Journal of clinical and aesthetic dermatology, 7(11), 16–24. 2. Ayala-Fontánez, N., Soler, D. C., & McCormick, T. S. (2016). Current knowledge on psoriasis and autoimmune diseases. Psoriasis, 6, 7–32. https://doi.org/10.2147/PTT.S64950 3. Barker J. N. (2001). Genetic aspects of psoriasis. Clinical and experimental dermatology, 26(4), 321–325. https://doi.org/10.1046/j.1365-2230.2001.00830.x 4. Baz, K., Cimen, M. Y., Kokturk, A., Yazici, A. C., Eskandari, G., Ikizoglu, G., Api, H., & Atik, U. (2003). Oxidant / antioxidant status in patients with psoriasis. Yonsei medical journal, 44(6), 987–990. https://doi.org/10.3349/ymj.2003.44.6.987 5. Behnam, S. M., Behnam, S. E., & Koo, J. Y. (2005). Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use. Journal of drugs in dermatology : JDD, 4(2), 189–194.
|
|